WSJ: Trump to draw executive order on healthcare prices

Amy Baxter | | Health Exec | Policy & Regulations

President Trump is planning to issue an executive order that will “compel the disclosure” of healthcare prices, according to The Wall Street Journal, which cited people familiar with the matter.

Insurers, doctors, hospitals and other industry stakeholders could be required to provide information about their negotiated and discounted costs of care. The move is in line with the Trump administration’s efforts to lower healthcare costs by promoting transparency. However, it is unclear what enforcement mechanism could be behind the future requirements.

Industry groups have spoken out against transparency rules, arguing they will actually lead to higher costs. A group of doctors supports the administration’s move. The executive order will likely come just days after Trump announced during an interview with ABC that he will introduce a new healthcare plan in the next few months.

See the full story below:

Trump to Issue Executive Order on Health-Care Price Transparency

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

HHS retracts Richardson Waiver in change to public comment policy
FDA issues Class I recall on newborn resuscitation devices
FDA announces recall of endoscope sheaths after 26 injuries
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk
Request for an American Board of Cardiovascular Medicine denied—cardiology groups ‘deeply disappointed’
Why cardiac CT adoption remains low among primary care providers

Around the web

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.

Cardiovascular Business
Request for an American Board of Cardiovascular Medicine denied—cardiology groups ‘deeply disappointed’

The ACC, AHA, HFSA, HRS and SCAI all worked together to try and make the new board a reality. Though their proposal has been denied, the groups say they are not done fighting. 

Cardiovascular Business
FDA sued over ‘reckless and arbitrary’ semaglutide decision

The Outsourcing Facilities Association, a Texas-based trade group, is alleging that supply issues still remain for Ozempic and Wegovy. The group believes the FDA has ignored those issues.